Real Money: Independent market insight from a veteran team of trusted Wall Street pros.
• Up-to-the-minute reports on market activity
• Actionable trade ideas
Real Money Pro: Professional tools and specific trade ideas for active investors.
• Information-packed market flow providing trade ideas, fast
• Dynamic interface with professional-grade analytical tools
• Full, unlimited access to Real Money
Latest Alert
May 23, 2013 | 03:43 PM EDT
We view this announcement of the replacement for its retiring executive as a positive and we remain bullish on the shares.
FULL ALERT »
Action Alerts PLUS: Jim Cramer and Stephanie Link actively manage a real money portfolio for Jim's charitable trust.
• Timely trade alerts including price targets
• Unique insight into market movements
• Guidance on how to trade right alongside Jim and Stephanie
Latest Alert
May 22, 2013 | 10:27 AM EDT
The stock has doubled over the past three months and we don't want to be greedy with our gains.
FULL ALERT »
Stocks Under $10: David Peltier manages a portfolio of affordable stocks with huge upside potential.
• Identify fast-growing small-cap stock opportunities
• Buy and sell alerts allow you to analyze overlooked opportunities quickly
• In-depth reports and research packed with proprietary analysis
Latest Alert
May 24, 2013 | 08:41 AM EDT
This name issued a near-perfect fiscal third-quarter earnings report and bumped its full-year guidance higher.
FULL ALERT »
Breakout Stocks: Bryan Ashenberg, CFA, manages a portfolio of small and mid-cap stocks with high growth potential.
• Identify industry-changing macrotrends in their infancy
• Timely trade alerts loaded with detailed research
• Frequent communication about all Bryan's portfolio holdings
Options Profits: Day in and day out, our team of professional options traders search for inventive plays for trading spikes in market activity, emerging trends, and breaking news and events. These veterans reveal all their charts and technical data — delivering daily strategies and insightful commentary written specifically for the options trader plus 40 options trade ideas per week!
Aegerion Pharmaceuticals Inc. (AEGR)
AEGR (NASDAQ:Drugs)
$60.39
-0.57
-0.94%
Today's Range: 60.22 - 61.33 |
AEGR Avg Daily Volume: 642,200
| Last Update: 05/24/13 - 10:01 AM EDT |
| Volume: 42,458 |
| YTD Performance: 129.51%
|
| Open: $60.61 |
| Previous Close: $60.96 |
| 52 Week Range: $12.87 -
$63.72 |
| Oustanding Shares: 28,819,111 |
| Market Cap: 1,678,713,216 |
6-Month Chart
TheStreet Ratings Grade for AEGR
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
10 |
10 |
11 |
10 |
| Moderate Buy |
1 |
1 |
1 |
1 |
| Hold |
0 |
0 |
0 |
0 |
| Moderate Sell |
0 |
0 |
0 |
0 |
| Strong Sell |
0 |
0 |
0 |
0 |
| Mean Rec. |
1.09 |
1.09 |
1.08 |
1.09 |
| Latest Dividend: |
0.00 |
| Latest Dividend Yield: |
0.00% |
| Dividend Ex-Date: |
12/31/69 |
| Price Earnings Ratio: |
-21.34 |
|
| Price Earnings Comparisons: |
| AEGR |
Sector Avg. |
S&P 500 |
| -21.34 |
0.00 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
98.94%
|
329.90%
|
0.00%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
0.00 |
0.00 |
0.00 |
| Net Income |
0.00 |
4.11 |
0.00 |
| EPS |
0.00 |
-0.18 |
0.00 |
| Earnings for AEGR: |
| EBITDA |
-0.06B |
| Revenue |
0.00B |
|
Average Earnings Estimates
;Qtr (09/13);FY (12/13);FY (12/14)&HEADING_LIST1=Qtr (06/12);Qtr (09/12);FY (12/12);FY (12/13)) |
|
| Average Estimate |
$-0.64 |
$-0.57 |
$-2.30 |
$0.26 |
| Number of Analysts |
6 |
5 |
7 |
7 |
| High Estimate |
$-0.55 |
$-0.47 |
$-2.05 |
$2.77 |
| Low Estimate |
$-0.78 |
$-0.76 |
$-2.78 |
$-1.69 |
| Prior Year |
$-0.60 |
$-0.59 |
$-2.58 |
$-2.30 |
| Growth Rate (Year over Year) |
-6.39% |
2.71% |
10.69% |
111.35% |
Dec 27, 2012 | 7:54 AM EST
Shares of AEGR now seen reaching $29, Jefferies said. Juxtapid approval. Buy rating.
By
Adam Feuerstein and Gregg Greenberg
Dec 14, 2012 | 5:30 AM EST
Adam Feuerstein, Sr. Columnist for TheStreet, says three big FDA drug approval decisions are the next big things to watch in biotech.
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by
Interactive Data. Company fundamental data provided by
Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by
Interactive Data Managed Solutions.
TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.
IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.
